Polatuzumab Vedotin With Bendamustine and Rituximab for Relapsed/Refractory High‐grade B‐cell Lymphoma: The Uk Experience

Northend, Michael; Wilson, William T.; Osborne, Wendy; Fox, Christopher P.; Davies, Andrew; El‐Sharkawi, Dima; Phillips, E.; Sim, Hau Wui; Sadullah, Shalal; Shah, Nimish; Peng, Ying Ying; Qureshi, Iman; Addada, Juanah; Mora, R. F.; Phillips, Neil; Kühnl, Andrea; Davies, Elizabeth; Wrench, David; McKay, Pam; Karpha, Indrani; Cowley, Anna; Karim, Raghad; Challenor, Sarah; Singh, Vikram; Combes, Burton; Auer, Rebecca; Williams, Chris; Broom, Angus; Roddie, Claire; Townsend, William

doi:10.1002/hon.86_2880

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a multi-center retrospective study of polatuzumab for patients with DLBCL who relapsed after SOC CARs therapy, a response was achieved in 45% patients, including CR in 14% patients and PR in 30% with a median OS of 16 weeks [ 82 ]. In the United Kingdom, patients with DLBCL (133 patients) ineligible for stem cell transplantation who received polatuzumab vedotin with bendamustine and rituximab, had an ORR of 57.0% (32.8% CR) [ 20 ].…”

Section: Overview Of Immunological Interventions In the Management Of...mentioning

confidence: 99%

Harnessing the Immune System: An Effective Way to Manage Diffuse Large B-Cell Lymphoma

Visweshwar,

Rico,

Killeen

et al. 2023

J Hematol

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) is a heterogenous hematological disorder with malignant potential controlled by immunological characteristics of the tumor microenvironment. Rapid breakthrough in the molecular pathways has made immunological approaches the main anchor in the management of DLBCL, with or without chemotherapeutic agents. Rituximab was the first monoclonal antibody approved for the treatment of DLBCL. Following rituximab that transformed the therapeutic landscape, other novel immunological agents including chimeric antigen T-cell therapy have reshaped the management of relapsed/refractory DLBCL. However, resistance and refractory state remain a challenge in the management of DLBCL. For this literature review, we screened articles from Medline, Embase, Cochrane databases and the European/North American guidelines from March 2010 through October 2022 for DLBCL. Here we discuss immunological agents that will significantly affect future treatment of this aggressive type of lymphoma.

show abstract

Section: Overview Of Immunological Interventions In the Management Of...mentioning

confidence: 99%

Harnessing the Immune System: An Effective Way to Manage Diffuse Large B-Cell Lymphoma

Visweshwar,

Rico,

Killeen

et al. 2023

J Hematol

View full text Add to dashboard Cite

show abstract

Meta-analysis of response rates to first-line salvage treatment after CAR-T therapy failure in large B-cell lymphoma patients

Tomasik,

Bilicki,

Basak

2024

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab

Papageorgiou

Thomopoulos

Liaskas

et al. 2022

Cancers

View full text Add to dashboard Cite

Although rituximab has revolutionized the treatment of diffuse large B-cell lymphoma (DLBCL), a significant proportion of patients experience refractory disease or relapse early after the end of treatment. The lack of effective treatment options in the relapsed/refractory (R/R) setting had made the prognosis of these patients dismal. The initial enthusiasm for novel anti-CD20 antibodies had been short-lived as they failed to prove their superiority to rituximab. Therefore, research has focused on developing novel agents with a unique mechanism of action. Among them, two antibody-drug conjugates, namely polatuzumab vedotin (PolaV) and loncastuximab tesirine, along with tafasitamab, an anti-CD19 bioengineered antibody, have been approved for the treatment of R/R DLBCL. Whereas PolaV has been FDA and EMA approved, EMA has not approved loncastuximab tesirine and tafasitamab yet. Results from randomized trials, as well as real-life data for PolaV have been promising. Novel agents as bispecific antibodies bridging CD3 on T-cells to CD20 have shown very promising results in clinical trials and are expected to gain approval for treatment of R/R DLBCL soon. As the therapeutic armamentarium against DLBCL is expanding, an improvement in survival of patients with R/R and higher cure rates might soon become evident.

show abstract

Polatuzumab Vedotin With Bendamustine and Rituximab for Relapsed/Refractory High‐grade B‐cell Lymphoma: The Uk Experience

Cited by 3 publications

References 0 publications

Harnessing the Immune System: An Effective Way to Manage Diffuse Large B-Cell Lymphoma

Harnessing the Immune System: An Effective Way to Manage Diffuse Large B-Cell Lymphoma

Meta-analysis of response rates to first-line salvage treatment after CAR-T therapy failure in large B-cell lymphoma patients

Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab

Contact Info

Product

Resources

About